Pharmacological Blockade of the Adenosine A2B Receptor Is Protective of Proteinuria in Diabetic Rats, through Affecting Focal Adhesion Kinase Activation and the Adhesion Dynamics of Podocytes

Cells. 2024 May 16;13(10):846. doi: 10.3390/cells13100846.

Abstract

Induction of the adenosine receptor A2B (A2BAR) expression in diabetic glomeruli correlates with an increased abundance of its endogenous ligand adenosine and the progression of kidney dysfunction. Remarkably, A2BAR antagonism protects from proteinuria in experimental diabetic nephropathy. We found that A2BAR antagonism preserves the arrangement of podocytes on the glomerular filtration barrier, reduces diabetes-induced focal adhesion kinase (FAK) activation, and attenuates podocyte foot processes effacement. In spreading assays using human podocytes in vitro, adenosine enhanced the rate of cell body expansion on laminin-coated glass and promoted peripheral pY397-FAK subcellular distribution, while selective A2BAR antagonism impeded these effects and attenuated the migratory capability of podocytes. Increased phosphorylation of the Myosin2A light chain accompanied the effects of adenosine. Furthermore, when the A2BAR was stimulated, the cells expanded more broadly and more staining of pS19 myosin was detected which co-localized with actin cables, suggesting increased contractility potential in cells planted onto a matrix with a stiffness similar to of the glomerular basement membrane. We conclude that A2BAR is involved in adhesion dynamics and contractile actin bundle formation, leading to podocyte foot processes effacement. The antagonism of this receptor may be an alternative to the intervention of glomerular barrier deterioration and proteinuria in the diabetic kidney disease.

Keywords: adenosine receptors; diabetic nephropathy; podocyte effacement; proteinuria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / metabolism
  • Adenosine / pharmacology
  • Adenosine A2 Receptor Antagonists / pharmacology
  • Animals
  • Cell Adhesion* / drug effects
  • Cell Movement / drug effects
  • Diabetes Mellitus, Experimental* / complications
  • Diabetes Mellitus, Experimental* / metabolism
  • Diabetes Mellitus, Experimental* / pathology
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / metabolism
  • Diabetic Nephropathies / pathology
  • Focal Adhesion Protein-Tyrosine Kinases* / drug effects
  • Focal Adhesion Protein-Tyrosine Kinases* / metabolism
  • Humans
  • Male
  • Myosin Light Chains / metabolism
  • Phosphorylation / drug effects
  • Podocytes* / drug effects
  • Podocytes* / metabolism
  • Podocytes* / pathology
  • Proteinuria* / metabolism
  • Rats
  • Receptor, Adenosine A2B* / drug effects
  • Receptor, Adenosine A2B* / metabolism

Substances

  • Adenosine
  • Adenosine A2 Receptor Antagonists
  • Focal Adhesion Protein-Tyrosine Kinases
  • Myosin Light Chains
  • Receptor, Adenosine A2B